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Summary
The POU-domain transcription factor Oct-4 is nor-
mally expressed in pluripotent cells of the mamma-
lian embryo. In addition, germ-cell tumors and a few
somatic tumors show detectable expression of Oct-4.
While Oct-4’s role during preimplantation develop-
ment is to maintain embryonic cells in a pluripotent
state, little is known about its potential oncogenic
properties. Here we investigate the effect of ectopic
Oct-4 expression on somatic tissues of adult mice
using a doxycycline-dependent expression system.
Activation of Oct-4 results in dysplastic growths in
epithelial tissues that are dependent on continuous
Oct-4 expression. Dysplastic lesions show an expan-
sion of progenitor cells and increased -catenin tran-
scriptional activity. In the intestine, Oct-4 expression
causes dysplasia by inhibiting cellular differentiation
in a manner similar to that in embryonic cells. These
data show that certain adult progenitors remain com-
petent to interpret key embryonic signals and support
the notion that progenitor cells are a driving force in
tumorigenesis.
Introduction
Oct-4 (Oct-3 encoded by Pou5f1) belongs to the family
of POU-domain transcription factors that are involved
in the regulation of cell growth and differentiation in a
variety of tissues (Ryan and Rosenfeld, 1997). Oct-4 ex-
pression is normally confined to pluripotent cells of the
developing embryo, including epiblast cells, primordial
germ cells, and their in vitro counterparts, embryonic
stem (ES) and embryonic germ (EG) cells, respectively
(Pesce and Scholer, 2001). In addition, Oct-4 is tran-
siently expressed in the developing endoderm (Palmieri
et al., 1994) and neurectoderm (Reim and Brand, 2002)
of the embryo, where it may contribute to the specifica-
tion of cell fate. In mice, a loss-of-function mutation for
Oct-4 results in early embryonic lethality because of the
inappropriate differentiation of pluripotent epiblast cells
into trophectoderm (Nichols et al., 1998). Similarly,
downregulation of Oct-4 in ES cells induces trophec-
toderm differentiation, whereas overexpression induces
differentiation into extraembryonic mesoderm and en-
doderm (Niwa et al., 2000), demonstrating that Oct-4 is*Correspondence: jaenisch@wi.mit.edu
3 These authors contributed equally to this work.a crucial and dose-dependent determinant of pluripo-
tency in embryonic cells. Consistent with its role in
maintaining pluripotency, the reactivation of Oct-4 has
been correlated with efficient reprogramming of so-
matic cells following nuclear transfer into oocytes (Boi-
ani et al., 2002; Bortvin et al., 2003; Byrne et al., 2003)
or cell fusion of somatic cells with ES cells (Kimura et
al., 2004; Tada et al., 2001). Moreover, ectopic expres-
sion of Oct-4 in certain somatic cells has been associ-
ated with active dedifferentiation (Shimazaki et al.,
1993).
Oct-4 and other pluripotency-associated genes have
recently been reported to be expressed in germ-cell
cancers (Cheng, 2004; Cheng et al., 2004; Clark et al.,
2004; Gidekel et al., 2003; Jones et al., 2004; Looijenga
et al., 2003a), suggesting that (1) primordial germ cells
(PGCs) that usually express these genes may be the
cells of origin in certain cancers of the gonads and (2)
aberrant expression of Oct-4 may contribute to PGCs’
malignant transformation, possibly by providing a sur-
vival signal (Kehler et al., 2004). The finding that overex-
pression of Oct-4 in a mouse teratoma model causes
a more malignant histological phenotype while forced
downregulation prevents tumor growth (Gidekel et al.,
2003) is in agreement with this notion. Furthermore,
most human germ-cell tumors show genomic amplifi-
cation of chromosome 12p, which harbors several
genes associated with pluripotency, such as Gdf3, Na-
nog, Stella, and an Oct-4 pseudogene (Chambers and
Smith, 2004; Honecker et al., 2004; Jones and Baylin,
2002; Pain et al., 2005). This may indicate that overex-
pression of some of these factors is oncogenic (Brick-
man and Burdon, 2002; Clark et al., 2004; Looijenga et
al., 2003b; Sperger et al., 2003).
The reactivation of pluripotency-associated genes
has also been observed in various somatic cancer cells
(Monk and Holding, 2001), but the relevance of this
finding is unclear. For example, Oct-4 was found to be
expressed in different breast cancer cell lines (Jin et al.,
1999; Wang et al., 2003) and a colon cancer cell line
(Steingart et al., 2002) in contrast to untransformed cell
lines. Moreover, tumor tissue arrays detected Oct-4
protein in rare human kidney and lung cancer samples
(Looijenga et al., 2003a). Independent studies reported
the detection of Oct-4 protein in adult human stem cells
and cultured tumor cell lines (Tai et al., 2005) as well as
in rare fetal brain cells (Okuda et al., 2004). Yamaguchi
and coworkers have recently described a case of an
undifferentiated bone tumor with genomic fusion be-
tween EWSR1 and POU5F1, thus indicating transloca-
tion as a mechanism for OCT-4 reactivation in a human
cancer (Yamaguchi et al., 2005). In addition to Oct-4,
other genes predominantly expressed in pluripotent
cells, such as the nodal coreceptor Cripto (Tdgf), have
been shown to be overexpressed in different somatic
types of cancer (Adamson et al., 2002); ectopic expres-
sion of either Cripto, Oct-4, or the ES-cell-specific E-Ras
gene in immortalized murine cells results in their trans-
formation (Adamson et al., 2002; Ciardiello et al., 1991;
Cell
466Gidekel et al., 2003; Takahashi et al., 2003), reinforcing O
the idea that the reactivation of some pluripotency- s
associated factors may contribute to tumorigenesis in f
somatic tissues. n
Similar to the role of PGCs in germ-cell cancer, so- T
matic stem cells may be the cells of origin in many so- d
matic cancers. Somatic stem cells represent a rare cell t
type capable of self-renewal and differentiation into one w
or more mature cell types in order to maintain and re- t
pair adult tissues (Reya et al., 2001) and may be the d
preferred targets for transformation because of their t
high proliferative capacity (Al-Hajj et al., 2004; Pardal et
al., 2003; Reya et al., 2001). Indeed, hematopoietic
stem cells were suggested recently to play a key role O
in a mouse model of myeloproliferative disorder (Pas- T
segue et al., 2004). The notion that tumors arise from s
transformed stem cells or progenitor cells that have ac- i
quired mutations conferring immortality is compatible b
with the concept of “cancer stem cells” that are t
thought to constitute a rare population of cells with in- t
definite proliferation potential that drives the formation o
and growth of tumors (Weissman, 2000). v
In order to test the effect of ectopic Oct-4 expression g
on somatic differentiation and tumorigenesis, we have G
established a mouse model in which Oct-4 can be acti- T
vated in an inducible and reversible manner in a variety a
of somatic tissues. d
i
Results w
u
Inducible Expression of Oct-4 in Mice l
We engineered V6.5 ES cells to express the M2 reverse d
tetracycline transactivator (M2-rtTA) (Gossen and Bu- a
jard, 1992; Urlinger et al., 2000) constitutively from the t
ROSA26 locus (ROSA26::rtTA) (Figure 1A). A doxycy- n
cline-responsive element controlling Oct-4 expression
f
was targeted downstream of the collagen 1a1 locus by
m
frt/Flpase-mediated site-specific integration (Col1a1::
l
TetOP-Oct-4) (McCreath et al., 2000). Twenty-four out
mof twenty-four analyzed clones (100%) were found to
bhave integrated the transgene correctly as determined
gby Southern blot analysis (data not shown).
tWe injected targeted ES cells into tetraploid blasto-
hcysts to obtain entirely ES-cell-derived animals (ES
omice) (Eggan et al., 2001; Nagy et al., 1993). Exposure
Sof cultured fibroblasts from ES mice to doxycycline
Mshowed a strong upregulation of Oct-4 message (Figure
d1B) and protein (Figure 1C) to a level that was compara-
mble to that in ES cells, demonstrating the functionality
cand robustness of the inducible system. Fibroblasts in-
mduced to express Oct-4 exhibited a morphological
echange into large, flat cells (Figure 1D) and a 2-fold re-
mduction in cell proliferation (Figure 1E). This phenotype
Ewas completely reversible upon withdrawal of the drug
s(data not shown). We did not observe any obvious dif-
cferences in cell death or replicative senescence after
oprolonged passage of cells (data not shown).
wTo determine the levels of Oct-4 induction in various
mtissues of adult mice, we analyzed animals that were
tgiven doxycycline in the drinking water for 3 days. Tis-
tsues were harvested and analyzed by Northern blot
panalysis (Figure 1F) and immunohistochemistry (Fig-
ures 3–5). As summarized in Table 1, highest levels of lct-4 expression were found in the liver, bone marrow,
tomach, intestine, and skin, and lower levels were
ound in the heart, lungs, kidney, spleen, and thymus;
o expression was detected in the brain and testes.
he lack of induction in the brain and testes is likely
ue to the inability of doxycycline to efficiently cross
he blood-brain and blood-testis barriers. Mice that
ere not exposed to doxycycline did not show any de-
ectable Oct-4 expression (Figure 1F and Figures 3–5),
emonstrating a tight, doxycycline-dependent regula-
ion in multiple somatic tissues.
ct-4 Expression Causes Dysplasia in Adult Mice
o assess the long-term effect of ectopic Oct-4 expres-
ion in vivo, we fed adult mice doxycycline in the drink-
ng water. Surprisingly, Oct-4-induced animals (n = 20)
ecame morbid after only 3–5 days of doxycycline
reatment, as manifested by severe dehydration and le-
hargic appearance, and usually died after 5–10 days
f treatment. Histologic analysis of tissue samples re-
ealed signs of abnormal cell proliferation in several or-
ans as early as 2 days after Oct-4 induction.
astrointestinal Tract
he stomach and entire intestine, including the cecum
nd colon, showed dysplastic growth after 5 days of
oxycycline treatment. The proximal part of the small
ntestine displayed the most severe phenotype, in
hich abnormal cells almost obstructed the lumen (Fig-
re 2B). Dysplastic cells were found in the entire epithe-
ium rather than in focal areas, suggesting that ad-
itional genetic alterations were not required for
bnormal cell proliferation. These cells showed struc-
ural and cytological dysplasia that mimic adenocarci-
oma in situ (Figure 2C). As in the intestine, cells of the
orestomach showed a marked atypia and increased
itotic activity throughout the squamous epithelial
ayer (Figures 2E and 2F). In certain regions the base-
ent membrane appeared unclear, a feature resem-
ling microinvasion in squamous cell carcinoma. In the
landular stomach, dysplastic glands were detected in
he pyloric mucosa, and fundic glands often showed
yperplastic changes (data not shown). The histology
f the pyloric mucosa resembled high-grade dysplasia.
kin
ice that had been treated with doxycycline for 5–10
ays showed mild to moderate dysplasia in the epider-
is and an increase of immature cells in the hair folli-
les of the skin (data not shown). To circumvent the
orbidity of Oct-4-induced animals and to study the
ffect of prolonged Oct-4 induction on the skin, chi-
eric mice were generated by injecting Oct-4-inducible
S cells into wild-type blastocysts. In this approach,
omatic tissues are composed of a mixture of wild-type
ells and Oct-4-inducible cells. Mice that showed obvi-
us coat-color chimerism (about 80% of newborn mice)
ere kept for further analyses. Three-week-old chi-
eric mice that had been induced with doxycycline un-
il the age of 6 weeks developed multiple visible skin
umors (n = 3) (Figure 2G). The tumors consisted of dys-
lastic cells that had irregular, enlarged nuclei with
arge nucleoli, and the lesions showed obvious invasive
Oct-4 Expands Adult Progenitor Cells
467Figure 1. Characterization of Oct-4-Inducible Cells and Mice
(A) Schematic representation of transgenes used to produce Oct-4-inducible ES cells and mice. The M2-rtTA gene was targeted into the
ROSA26 locus under control of the ROSA promoter. A cassette containing the Oct-4 cDNA under the control of the doxycycline (DOX)-
responsive promoter was “flipped” downstream of the collagen locus (see Experimental Procedures). SA, splice acceptor; pA, polyadenylation
signal; TetOP, tetracycline/doxycycline-responsive operator. Black arrowheads indicate transcriptional start sites.
(B) Doxycycline-dependent induction of Oct-4 RNA in cultured fibroblasts from transgenic mice as determined by Northern blot analysis.
Blots were stained with methylene blue to control for equal loading. ES, ES cells; M−, MEFs (murine embryonic fibroblasts) cultured without
doxycycline, M+, MEFs cultured in the presence of doxycycline.
(C) Doxycycline-dependent induction of Oct-4 protein in cultured fibroblasts from transgenic mice as determined by Western blot analysis.
Blots were stained with Ponceau red to control for equal loading.
(D) Morphological change of fibroblasts upon doxycycline-dependent induction of Oct-4 expression.
(E) Proliferation curves of doxycycline-induced and -uninduced tail fibroblasts. Time points represent average values from duplicate measure-
ments and their standard deviations.
(F) Oct-4 induction in different tissues of mice. Mice containing both transgenes (M2-rtTA/TetOP-Oct-4) were fed doxycycline in the drinking
water for 3 days. Control mice were littermates with the same genotype but not exposed to doxycycline. Br, brain; Li, liver; H, heart; Lu, lung;
K, kidney; Bm, bone marrow; Sp, spleen; T, thymus; St, stomach; I, intestine; Sk, skin; Te, testis; ES, ES cells.growth toward the subcutaneous tissue (Figures 2H
and 2I).
Cell-Autonomous Effect of Oct-4 Expression
The effect of ectopic Oct-4 expression on dysplastic
growth could be cell-autonomous or non-cell-autono-
mous. To address this question, we generated chimeric
mice with Oct-4-inducible ES cells that also carried a
constitutive GFP marker allowing their detection in
chimeric tissues. Chimeric animals exposed to doxycy-
cline developed the same types of lesions in intestine,
colon, stomach, and skin as fully transgenic mice. Co-lon sections showed the presence of focal lesions that
coincided with areas of strong Oct-4 expression (Fig-
ures 3A and 3B), whereas adjacent epithelia appeared
normal and were negative for Oct-4 signal. Moreover,
sites of tumor growth were positive for GFP, in contrast
to adjacent normal tissue that was GFP negative, thus
demonstrating their origin from the ES cells (data not
shown). A similar result was obtained for dysplastic
lesions of the skin of chimeric mice (Figures 3C and
3D). This indicated that hyperplastic and dysplastic
growth was the result of a cell-autonomous effect of
Oct-4 expression.
Cell
468Table 1. Effect of Ectopic Oct-4 Expression on Cellular Proliferation and Differentiation
Tissue Oct-4 Expression Levels Phenotypes Changes in Differentiation
(RNA/Protein)
Skin ++++ Tumors with invasion into subcutaneous Tumors originate from outer-root-sheath
tissue, increased number of proliferating progenitors (K17 positive; negative for
cells (Ki-67-positive cells) AE13, AE15, and K6)
Intestine ++++ Dysplasia resembling adenocarcinoma Increased size of crypt compartment
in situ, increased number of proliferating (β-catenin-positive cells)/lack of villus
cells differentiation (AP/PAS-positive cells)
Forestomach ++++ Dysplasia resembling squamous cell Lack of differentiation into granular and
carcinoma, increased number of cornified cell layers
proliferating cells
Glandular stomach ++++ Severe dysplasia, increased proliferation N/D
Liver ++++ N/D N/D
Bone marrow ++++ N/D N/D
Spleen ++ Atrophic N/D
Lungs ++ N/D N/D
Lymph nodes ++ N/D N/D
Thymus + Atrophic Lack of CD4/CD8 double-positive cells
Kidney + N/D N/D
Heart + N/D N/D
Fibroblasts ++++ Proliferation defect N/D
No expression detected in brain and testis. N/D, not detected.intestinal epithelium, which contains largely stem and (Figures 4J–4O). Our results indicate that the dysplastic
Figure 2. Dysplasia in Oct-4-Inducible Mice
Figures show H&E staining of paraffin-
embedded tissue sections.
(A–C) Small intestine. Oct-4 induction results
in dysplastic growth in the small intestine
(B). Abnormal cells show cytological and
structural dysplasia (C) with frequent mitotic
figures (arrowheads), whereas control mice
retain normal crypt-villus structure (A).
(D–F) Forestomach. Oct-4 mice show a
thickened epithelium (E) consisting of atypi-
cal cells with enlarged nuclei and prominent
nucleoli as well as increased mitotic figures
(F, arrowheads). Oct-4 mice also show a lack
of differentiation into granular and cornified
cell layers (F), unlike control mice (D).
(G–I) Skin. Phenotype of chimeric mouse
showing multiple skin tumors (G). Histologi-
cally, tumors resemble skin cancer (H) with
apparent invasive growth toward the subcu-
taneous tissue (I, arrowheads). Scale bars:
500 m (A, B, D, E, and H); 50 m (C and F);
100 m (I).Expansion of Progenitor Cells in Dysplastic Lesions t
2We noticed that dysplastic lesions of the intestine and
skin lacked differentiated cells and appeared morpho- e
alogically immature (Figure 2). Increased numbers of im-
mature cells in tumors could be due to a selective ex- c
4pansion of progenitor cells or a dedifferentiation of
more mature cells into progenitor cells. To distinguish s
abetween these possibilities, we compared the epithelia
of the small intestine of mice that had been treated with l
pdoxycycline for 0, 2, or 5 days. As shown in Figure 4D,
Ki-67-positive proliferating cells of control mice were w
(confined to the crypt compartment at the base of theransient-amplifying progenitor cells (Sancho et al.,
003). Doxycycline induction resulted in a progressive
xpansion of the proliferative zone (Figures 4E and 4F)
nd the replacement of postmitotic and differentiated
ells lining the villus after 5 days of treatment (Figure
F). β-catenin, which is predominantly expressed in the
tem and progenitor cells of the intestine (Sancho et
l., 2003) (Figure 4G), was detectable throughout the
esion (Figures 4H and 4I). Conversely, alkaline phos-
hatase (AP) and periodic acid Schiff (PAS) markers,
hich are specific for differentiated cells lining the villus
Cheng and Leblond, 1974), were progressively lost
Oct-4 Expands Adult Progenitor Cells
469Figure 3. Ectopic Oct-4 Expression Causes Cell-Autonomous Dys-
plasia
Chimeras show focal dysplastic areas in the crypts of the colon (A)
and the skin (C) that coincide with areas of Oct-4 expression
(brown signal) (B and D), whereas adjacent tissue appears normal
and is negative for Oct-4 signal. The border between dysplastic
and normal colon tissue is indicated by a dotted line. Scale bars:
80 m (A); 500 m (C).cells originated from the crypt compartment and ex-
panded toward the lumen of the intestine likely due to
an Oct-4-induced block in differentiation.
To identify the cellular compartment that undergoes
hyperproliferation in the skin of Oct-4-inducible mice,
we analyzed skin sections of chimeric animals that had
been induced with doxycycline for 0, 2, or 3 weeks. Ki-
67-positive cells were detected in the epidermis and
outer root sheath of the hair follicle 2 weeks after
Oct-4 induction (Figure 5E) and throughout the dysplas-
tic lesion after 3 weeks of induction (Figure 5F). Prolifer-
ating cells expressed keratin 17—a marker specific for
the outer root sheath, which contains progenitor and
stem cells (Figures 5G–5I) (McGowan and Coulombe,
1998)—and failed to express AE13, which is normally
restricted to the differentiated zones of the hair shaft
and cuticle of the hair follicle (Lynch et al., 1986) (Fig-
ures 5J–5L). Likewise, AE15, which marks the differenti-
ated cells of the inner root sheath and medulla (O’Guin
et al., 1992), and keratin 6 (data not shown), which
marks differentiated cells of the companion layer of the
hair follicle (McGowan and Coulombe, 1998), were ab-
sent in tumor sections (Figures 5M–5O). Thus, as in the
intestine, Oct-4 expression expands immature cells of
the hair follicle, leading to dysplastic lesions in the skin.
The Dysplastic Phenotype Is Fully Reversible
In order to determine whether the Oct-4-induced dys-
plastic phenotype was dependent on continuous Oct-4
expression, we induced a transgenic mouse with doxycy-
cline until it became morbid (5 days) and then withdrew
the drug. The mouse recovered completely and was
sacrificed 3 weeks later to analyze tissue sections. No
tumors or abnormal cell proliferation were detected inany of the analyzed organs, including intestine, stom-
ach, and skin (data not shown).
To assess whether longer exposure to doxycycline
might yield growths due to irreversible changes that
would render the tumor phenotype doxycycline inde-
pendent, we analyzed chimeric animals that had been
exposed to doxycycline for 3 weeks and had developed
multiple skin lesions on the back (Figure 2G). Biopsies
of these skin tumors showed invasion through the
basement membrane into the underlying tissue (Figures
2I and 6A). When doxycycline was withdrawn for 3
weeks, the overt skin tumors disappeared completely
within 10 days, and subsequent histological analysis of
the regressed tumor area showed no signs of dysplas-
tic or neoplastic growth. Instead, tumor tissue was re-
placed with granulation tissue containing fibroblasts
and small vessels (Figure 6B). These results demon-
strate that this Oct-4-induced tumor growth is fully re-
versible, indicating that ectopic Oct-4 expression is
continuously required to maintain the dysplastic phe-
notype.
Differentiation of Dysplastic Intestinal Cells
upon Loss of Oct-4 Expression
The observation that intestinal lesions contain in-
creased numbers of β-catenin-positive immature cells
emanating from the crypt compartment but lack cells
expressing differentiation markers indicates that Oct-4
expression increases the number of dividing progenitor
cells by inhibiting their differentiation rather than, or in
addition to, actively stimulating their proliferation. To
examine whether the Oct-4-mediated block in differen-
tiation was reversible, we followed the fate of dysplas-
tic intestinal cells upon doxycycline withdrawal. Mice
were induced with doxycycline for 5 days and injected
with a single dose of BrdU just prior to doxycycline
withdrawal, thereby allowing proliferating dysplastic
cells to incorporate BrdU into their DNA. Two days
after doxycycline withdrawal, intestinal sections were
stained with BrdU antibody to identify any previously
proliferating cells (see Figure 6C for scheme). In control
mice that were pulsed with BrdU 2 days prior to analy-
sis, BrdU-positive cells were detected in a confined
area between the crypt compartment, where proliferat-
ing progenitor cells are located, and the villus compart-
ment, where differentiating cells reach their final desti-
nation and become postmitotic (Figure 6D). This
indicated that BrdU-labeled progenitor cells of control
mice had begun to differentiate and migrate toward the
lumen of the intestine. In contrast, BrdU-positive cells
of Oct-4-induced mice were found throughout the lu-
men of the intestine 2 days after the BrdU pulse, dem-
onstrating that the labeled cells persisted after doxycy-
cline withdrawal (Figure 6E). Importantly, BrdU-positive
cells appeared to be differentiated (Figure 6F) and ex-
pressed the differentiation markers AP, which marks
absorptive cells (Figure 6G), and PAS, which marks
goblet cells (Figure 6H), but were negative for Ki-67,
which marks actively proliferating cells (data not
shown). We conclude that Oct-4 induction reversibly in-
hibits the differentiation of either a single multipotent
progenitor cell or a group of unipotent progenitor cells
of the intestinal crypt compartment, thus resulting in
their proliferative expansion.
Cell
470Figure 4. Expansion of Progenitor Cells and
Loss of Differentiated Cells in the Intestine
Robust upregulation of Oct-4 protein through-
out the intestinal epithelium after doxycy-
cline induction (B and C) compared with
control (A). Ki-67 staining shows proliferative
expansion of the progenitor-cell compart-
ment over time, marked by arrows (E and F).
Proliferative cells are normally confined to
the crypt compartment in control animals
(D). High levels of β-catenin signal are de-
tected in the stem-cell-containing crypt epi-
thelium (G), with low levels in differentiated
cells (villus epithelium). Doxycycline-induced
mice show strong staining in the epithelium
(H and I), including cells at the luminal side
of the intestine that are not proliferating (H).
Intestinal alkaline phosphatase (AP) activity
(red staining) is localized to differentiated
cells of the villi in control mice (J), whereas
no activity is observed in dysplastic cells (K
and L). Similarly, PAS staining, which marks
differentiated absorptive cells (M), is absent
in dysplastic lesions (N and O). Scale bars:
250 m (A and B); 350 m (C).Increased Levels of Transcriptionally Active s
4-Catenin in Intestinal Cells
Wnt/β-catenin signaling has been demonstrated to be t
pimportant for the self-renewal and differentiation of
many different stem and progenitor cells (Wang and w
bWynshaw-Boris, 2004), and dysregulation of compo-
nents of this pathway has been shown to cause cancer e
ain animal models (Lo Celso et al., 2004; Gat et al., 1998;
Giles et al., 2003; Li et al., 2003; Liu et al., 2004; van de t
eWetering et al., 2002). To explore whether there is an
increase in activated β-catenin, we analyzed intestinal g
csections of ES-cell-chimeric mice for nuclear β-catenin,
the transcriptional downstream effector of the canonical e
iWnt pathway (Moon et al., 2004). Transgenic ES cells that
constitutively expressed GFP from the ROSA26 locus al- u
lowed us to distinguish ES-cell-derived cells from host-
derived cells in chimeric mice. As shown in Figure 7A, t
dES-cell-derived crypts have higher levels of β-catenin
than host-derived crypts, indicating that Oct-4 expres- o
csion results in elevated β-catenin levels.
To test whether elevated β-catenin levels resulted in in- c
ccreased transcriptional activity, we introduced a β-catenin-
responsive TCF/LEF-EGFP reporter transgene (van de t
aWetering et al., 1997) into otherwise-unmodified Oct-
4-inducible ES cells and produced mice by tetraploid p
icomplementation. As expected, in control mice GFPignal was enriched in the crypt cells, whereas in Oct-
-induced mice a strong GFP signal was displayed
hroughout the colonic epithelium (Figure 7B, top
anel). Areas that showed ectopic TCF/LEF activity
ere also positive for nuclear β-catenin signal (Figure 7,
ottom panel), thus corroborating the notion that Oct-4
xpression results in increased levels of transcriptionally
ctive β-catenin. To evaluate the activation of β-catenin
arget genes in intestinal lesions, we performed West-
rn blot analysis for EphB2, a TCF-4/β-catenin target
ene that encodes a receptor essential for the proper
ell positioning within the intestinal epithelium (Batlle
t al., 2002). Indeed, ectopic Oct-4 expression resulted
n increased levels of total β-catenin and a concomitant
pregulation of EphB2 (Figure 7C).
In the skin of adult mice we did not observe a consis-
ent activation of the TCF/LEF reporter upon Oct-4 in-
uction, possibly due to differences in the hair cycle
f analyzed mice. However, in skin sections of E17.5
himeric embryos that had been exposed to doxycy-
line in utero for 4 days, we noticed that Oct-4-positive
ells were also positive for β-catenin and appeared his-
ologically immature, whereas adjacent host-derived
reas were negative for Oct-4 and β-catenin and ap-
eared histologically differentiated (Figure 7D). Unlike
n adult skin and intestinal samples, we did not observe
Oct-4 Expands Adult Progenitor Cells
471Figure 5. Expansion of Immature Cells and
Loss of Differentiated Cells in the Skin
Strong expression of Oct-4 in doxycycline-
induced mice (B and C) compared with a
control (A). Proliferating Ki-67-positive cells
are initially detected in the outer root sheath
(open arrowheads in [E]) and epidermis
(filled arrowheads in [E]) after 2 weeks of in-
duction and are present throughout the tu-
mor after 3 weeks of induction (F). At 2
weeks, proliferating cells are positive for ker-
atin 17 (H), which is detected in immature
cells of the outer root sheath in control mice
(G, arrowhead). At 3 weeks, skin tumors uni-
formly express keratin 17 (I). (J)–(L) show
immunostaining for AE13, which is ex-
pressed in differentiated cells of the hair
shaft and cuticle (J, arrowhead) but is not
detected in skin tumors (K and L). Likewise,
differentiated cells positive for AE15, which
is specific for the inner root sheath and me-
dulla (M, arrowhead), are progressively lost
after Oct-4 expression (N and O). Scale bars:
250 m (A–C); 150 m (D–F).an increase in cell proliferation in fetal chimeric skin
sections (data not shown). Together, these data demon-
strate that Oct-4 induction results in ectopic β-catenin
expression in the intestine and embryonic skin.
Discussion
We have shown that ectopic expression of the embry-
onic POU-domain transcription factor Oct-4 in adult
mice results in dysplastic growth that is cell autono-
mous, dependent on continuous Oct-4 expression, and
restricted to epithelial tissues. Our results suggest that
the target cells of Oct-4-induced dysplasia are epithe-
lial progenitor and/or stem cells rather than differenti-
ated cells. Thus, in the intestinal tract, dysplastic cells
emanated from the crypt compartment, causing an ex-
pansion of morphologically undifferentiated cells that were
positive for β-catenin and the disappearance of cells ex-
pressing differentiation markers such as AP and PAS. De-
spite uniform Oct-4 induction and concomitant upregula-
tion of β-catenin in all layers of the intestinal epithelium
(Figure 4), only crypt progenitor cells responded with in-
creased proliferation, suggesting that Oct-4 may re-
quire immature cells in order to deregulate cell prolifer-ation and differentiation. Conversely, Oct-4 expression
in already-differentiated cells of the intestine or hair fol-
licle had no effect on the cellular phenotype, and ec-
topic expression of Oct-4 in differentiated fibroblasts
had even adverse effects on cell proliferation. As in the
intestine, the number of skin cells positive for K17, a
marker expressed in progenitor zones, was increased,
whereas cells expressing the differentiation markers
AE15 or AE13 were diminished or absent in doxycy-
cline-treated mice, suggesting that ectopic Oct-4 ex-
pression expands multipotent cells by inhibiting their
differentiation.
Withdrawal of doxycycline caused a complete rever-
sal of the tumor phenotype: in the intestine, differentia-
tion markers characteristic of absorptive and goblet
cells reappeared rapidly in the expanded cell popula-
tion, and invasive skin tumors fully regressed. These
observations are consistent with reports by others de-
scribing the differentiation of dysplastic or neoplastic
cells upon loss of oncogene expression (Felsher, 2004;
Hutchin et al., 2005; Shachaf et al., 2004).
The observation that ectopic Oct-4 expression ex-
panded the compartments of progenitor cells by inhib-
iting their differentiation is reminiscent of Oct-4’s nor-
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Figure 6. Oct-4 Expression Reversibly Inhibits Progenitor-Cell Dif-
oferentiation in the Intestine β
Dysplastic growth is doxycycline dependent. Skin biopsies of inva-
psive tumor before (A) and after (B) withdrawal of doxycycline. Note
replacement of dysplastic cells with granulation tissue (inset). (C)
tshows scheme of BrdU pulse-chase experiment to follow the fate
of tumor cells after doxycycline withdrawal. BrdU staining shows m
migration of proliferating cells from crypt compartment toward villi h
in control mice 2 days after BrdU pulse (D), whereas in Oct-4 mice, p
BrdU-positive cells are found in the entire lumen of the intestine O(E). Luminal cells of (E) appear differentiated by H&E staining (F)
eand are positive for the differentiation markers AP (G) and PAS (H)
Ain contrast to tumors before doxycycline withdrawal (insets in [F]–
s[H]). Scale bars: 500 m (A and B); 250 m (D–G); 100 m (H).
t
t
mal role in ES cells, where continuous expression is c
required to maintain pluripotency and stem-cell identity o
as well as to inhibit differentiation into trophectoderm d
(Figure 7E). This specific effect of Oct-4 on embryonic K
and committed stem cells is also in agreement with the O
results of others showing that overexpression of Oct-4 b
expands the proportion of immature cells in teratomas I
(Gidekel et al., 2003) as well as neural-cell populations a
derived from ES cells (Shimozaki et al., 2003). Also, ab- p
errant expression of Oct-4 is detected frequently in hu-
man testicular germ-cell tumors (Looijenga et al., i
2003a; Gidekel et al., 2003) and rarely in somatic can- a
cers (Jin et al., 1999; Looijenga et al., 2003a; Monk and t
Holding, 2001; Steingart et al., 2002; Tai et al., 2005; e
Wang et al., 2003). Although the cells of origin are not s
mknown for these tumors, progenitor or stem cells maye the targets. Thus, the specific effect of ectopic
ct-4 expression on progenitor cells in the adult may
eflect similarities between embryonic stem cells and
dult stem/progenitor cells (Figure 7E).
Oct-4 is not normally expressed in adult cells, yet its
ctopic activation appears to have an effect on somatic
tem/progenitor cells similar to its effect on ES cells.
his suggests that common signaling pathways may be
ctivated in both cell types in response to Oct-4 ex-
ression. We found that ectopic Oct-4 expression
esulted in elevated levels of transcriptionally active
-catenin in dysplastic intestinal cells and embryonic
kin tissue. Activation of the Wnt/β-catenin pathway
as been shown to be essential for the homeostasis of
ifferent somatic stem- and progenitor-cell compart-
ents (Alonso and Fuchs, 2003; Chenn and Walsh,
002; Polesskaya et al., 2003; Reya et al., 2003; Sancho
t al., 2003; Sato et al., 2004; Yamashita et al., 2003),
nd its dysregulation can lead to cancer (Lo Celso et
l., 2004; Gat et al., 1998; Giles et al., 2003; Li et al.,
003; Liu et al., 2004; van de Wetering et al., 2002) and,
erhaps, the generation of cancer stem cells (Jamieson
t al., 2004). Moreover, acute activation of the canonical
nt pathway in the intestine through deletion of the
pc tumor suppressor results in expansion of the crypt
ompartment, loss of differentiation, and morbidity
Sansom et al., 2004), which is strikingly similar to the
henotype of Oct-4-induced mice. Thus, activation of
he Wnt/β-catenin cascade may be one of the key
ownstream events of Oct-4-induced progenitor-cell
xpansion and tumor growth. It remains to be deter-
ined whether Oct-4 activates β-catenin directly or in-
irectly in this mouse model and whether β-catenin ac-
ivation by Oct-4 plays a physiological role. Moreover,
ur experiments did not address whether activation of
-catenin through Oct-4 is sufficient for the dysplastic
henotype.
Though a direct link between Oct-4 expression and
he Wnt pathway has not yet been described in mam-
als, the finding that a mutation of Pou2, the zebrafish
omolog of Oct-4, results in a reduction of Wnt1 ex-
ression is compatible with the interpretation that
ct-4 might act upstream of the Wnt pathway (Belting
t al., 2001; Burgess et al., 2002; Byrne et al., 2003).
lso, consistent with a possible role of the Wnts in
tem-cell identity of ES cells is the recent observation
hat pharmacological inhibition of GSK-3β, which an-
agonizes β-catenin, promotes the self-renewal of ES
ells (Sato et al., 2004), whereas aberrant expression
f components of the Wnt pathway interferes with the
ifferentiation potential of ES cells (Aubert et al., 2002;
ielman et al., 2002). In early mammalian development
ct-4 may upregulate β-catenin, and its activation may
e crucial for the maintenance of an immature state.
n contrast, dysregulation of Oct-4 and Wnt/β-catenin
ctivation in the adult may lead to progenitor-cell ex-
ansion and cancer (see Figure 7E for a model).
The severely dysplastic tissue phenotypes of Oct-4-
nducible mice indicate that Oct-4 can function potently
s an oncogene, and it is therefore puzzling that its ac-
ivation is rarely seen in somatic tumors. It may be that
ffective epigenetic mechanisms are in place to ensure
ilencing of this potent cancer gene during develop-
ent and in the adult. Indeed, several epigenetic si-
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473Figure 7. Ectopic Oct-4 Expression Results in Transcriptionally Active β-Catenin in Intestinal Cells
(A) ES-cell-derived intestinal cells of chimeric mice were identified by immunohistochemistry for GFP, which detects the ROSA26-EGFP
transgene (left panel, filled arrowheads). GFP-positive cells have elevated levels of nuclear β-catenin following Oct-4 induction (right panel)
and compared with host-derived cells (GFP-negative; open arrowheads).
(B) Top panel shows GFP staining of a TCF/LEF-EGFP-reporter mouse, which indicates transcriptionally active β-catenin. GFP signal is
predominantly seen in the crypt compartment of control mice (top left panel) but is found in the entire colonic epithelium of doxycycline-
treated mice (top right panel). Increased nuclear β-catenin signal is seen throughout the colonic epithelium of doxycycline-treated mice
(bottom left panel and magnification to the right), whereas no nuclear staining is detectable in controls (magnification at bottom right).
(C) Oct-4 protein levels in the proximal small intestine of doxycycline-treated mice correlate with β-catenin levels and its target gene EphB2.
Multiple bands on β-catenin blot indicate stabilized form (high-molecular-weight band) and degraded forms (lower-molecular-weight bands);
T, tumor (adenoma) from APCmin mouse with constitutively active β-catenin.
(D) Embryonic skin of E17.5 chimeric mouse treated with doxycycline for 4 days shows areas of undifferentiated and differentiated cells (top
panel, H&E). Oct-4 and β-catenin are specifically expressed in the undifferentiated cells (middle and bottom panels).
(E) Comparison of Oct-4’s effect on pluripotent ES cells (top) and multipotent progenitor cells (bottom). In ES cells, Oct-4 maintains the
pluripotent state by preventing differentiation into trophectoderm. Similarly, in adult progenitor cells, Oct-4 appears to maintain an immature
state by preventing differentiation into mature cells, ultimately leading to tumor formation. The Wnt/β-catenin pathway may be a potential
mediator of these effects. Scale bars: 70 m (A); 100 m (B); 80 m (D).
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474dlencing mechanisms have been shown to be involved
tin Oct-4 promoter regulation, such as DNA methylation
(Gidekel and Bergman, 2002; Hattori et al., 2004), his- R
tone H3 lysine 9 methylation (Kimura et al., 2004; Lee et T
al., 2004), and the binding of transcriptional repressors (
(Ben-Shushan et al., 1995). In agreement with the no- f
htion that somatic cells require effective silencing of the
2Oct-4 gene, overexpression of Oct-4 has been associ-
Rated with the lethality of embryos (Fuhrmann et al.,
w
2001; Ramos-Mejia et al., 2005). r
The reversible expansion of skin progenitor cells by O
Oct-4 induction may be of potential medical interest. r
Reversible Oct-4 expression in cells derived from the
Cepidermis may allow the expansion of keratinocyte pro-
3genitors, which could be used for skin regeneration.
o
Likewise, the reversible growth of intestinal crypt cells s
might facilitate the in vitro propagation of intestinal pre- t
cursor cells in order to study their role in tissue homeo-
Hstasis and tumorigenesis. Finally, because Oct-4 has
Nbeen shown to be a key factor for the reprogramming
mof somatic cells in nuclear transfer (Boiani et al., 2002;
sBortvin et al., 2003; Byrne et al., 2003), it may be pos- u
sible to enhance the reprogramming efficiency of so- f
matic donor cells by transient expression of Oct-4 in a
Ldonor cells.
L
gExperimental Procedures
a
aMolecular Cloning and Gene Targeting in ES Cells
pThe mouse Oct-4 ORF was amplified by RT-PCR from ES-cell cDNA
cusing the primers TGAGCCGTCTTTCCACCAG and AGAACAAAAT
iGAGTGACAGACA and cloned into pcr2.1-TOPO. Sequence-veri-
3fied Oct-4 cDNA was subcloned into a unique EcoRI site of pBS31.
ypBS31 was engineered to contain the PGK promoter followed by
wan ATG start codon and a frt site, a splice acceptor-double polyA
pcassette, the tetracycline operator with a CMV minimal promoter, a
uunique EcoRI site for subcloning, and an SV40 polyA signal, assem-
bled in Bluescript. V6.5 ES cells were targeted by homologous re-
Bcombination to introduce the M2-rtTA gene into the ROSA26 locus
Munder ROSA26 promoter control. These cells were retargeted down-
wstream of the Col1a1 locus with a construct containing a frt-flanked
MPGK-neomycin-resistance gene followed by a promoterless, ATG-
wless hygromycin-resistance gene. To flip-in the tetracycline-respon-
Asive Oct-4 construct into these cells, circular pBS31-Oct-4 plasmid
was cotransfected with a plasmid expressing the Flpe recombi-
nase, and ES cells were selected for hygromycin resistance. To la-
Abel ES cells with a constitutive marker, a SA-EGFP-pA cassette
was targeted into the ROSA26 locus. To introduce a TCF/LEF re-
Wporter into ES cells, the TCF/LEF binding sites plus a minimal TK
apromoter were PCR amplified from the TOPFLASH plasmid (Up-
astate), ligated to an EGFP-pA cassette (Clontech), and introduced
Ainto a ROSA26 targeting vector containing a stop cassette to termi-
Gnate transcription from the upstream ROSA26 promoter.
w
PGeneration of Mice
kFor diploid blastocyst injections, fertilized zygotes were isolated
Afrom the oviducts of day-0.5 pregnant B6D2F1 females and allowed
gto develop to the blastocyst stage in culture. For tetraploid blasto-
(cyst injections (Eggan et al., 2001), two-cell embryos derived from
B6D2F1 females were first electrofused in 0.3 M mannitol/0.3%
BSA using the LF-101 cell-fusion instrument (Protech International, R
Inc.). Between 5 and 15 ES cells were injected per blastocyst. R
These were transferred into day-2.5 pseudopregnant B6D2F1 re- A
cipient females. C-sections were performed 17 days later, and pups P
were fostered with lactating Swiss mice.
R
Doxycycline Induction
Mice were fed 0.2 or 2 mg/ml doxycycline in the drinking water A
tsupplemented with 10 mg/ml sucrose. Chimeric fetuses were in-uced by giving 2 mg/ml doxycycline to pregnant females. For cul-
ured cells, doxycycline was used at a concentration of 2 g/ml.
NA and Protein Analysis
otal RNA from organs and cells was extracted with Trizol Reagent
Invitrogen). Seven micrograms of RNA was run on a 1% agarose-
ormaldehyde gel, blotted onto Genescreen Plus (NEN) filters, and
ybridized overnight in Church buffer. For Western blot analysis,
5 g of protein extract was run on a 4%–15% gradient gel (Bio-
ad) and blotted onto nitrocellulose membrane. Intestinal epithelia
ere harvested by scraping the inside of the intestinal wall with a
azor blade. Antibodies against the following proteins were used:
ct-4 (Santa Cruz, H-134), β-catenin (BD Transduction Laborato-
ies), and EphB2 (R&D Systems).
ell Proliferation Analysis
× 104 cells were plated per well of a 12-well dish in the presence
r absence of 2 g/ml doxycycline in DMEM (10% FCS, penicillin/
treptomycin, β-mercaptoethanol, nonessential amino acids), and
wo wells were counted per time point.
istological Analysis
ormal and tumor tissue samples were fixed in 10% buffered for-
alin for 24 hr and embedded in paraffin. Sections (5 m) were
tained with hematoxylin and eosin (H&E), and serial sections were
sed for immunohistochemical analysis. Immunostaining was per-
ormed using an avidin-biotin immunoperoxidase assay. Primary
ntibodies were anti-Oct-3/4 (1:100 dilution; BD Transduction
aboratories), anti-β-catenin (1:1000 dilution; BD Transduction
aboratories), anti-keratin 6 and anti-keratin 17 (1:1000 dilution; a
ift from P. Coulombe), anti-trochohyalin (AE15; 1:100 dilution) and
nti-hair keratin (AE13; 1:10 dilution; a gift from Tung-Tien Sun),
nd anti-Ki-67 (1:250 dilution; Dako). Sections were incubated with
rimary antibodies for 24 hr and subsequently with biotinylated se-
ondary antibodies (Vector Laboratories) for 30 min., followed by
ncubation with avidin-coupled peroxidase (Vector Laboratories) for
0 min. Diaminobenzidine was used as a chromogen and hematox-
lin as the counterstain. For negative controls, primary antibodies
ere omitted. Intestinal AP activity was visualized by alkaline phos-
hatase substrate kit I (Vector Laboratories). PAS staining was
sed to identify mucus-producing goblet cells.
rdU Labeling
ice were injected intraperitoneally with 100 mg BrdU/kg body
eight, and doxycycline was withdrawn immediately after injection.
ice were sacrificed 48 hr after injection, and incorporated BrdU
as detected by immunostaining with anti-BrdU antibody (1:250;
ccurate Chemical & Scientific Corp.) as described above.
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